Adam Friedman, MD, FAAD

A panelist discusses how mechanistic insights and head-to-head data are reshaping systemic therapy development, trial design, and personalized treatment strategies.

Renata Block, DMSc, MMS, PA-C, interviews Adam Friedman, MD, FAAD, about his research into cannabidiol’s photoprotective potential, clinical trial design, and future directions.

Adam Friedman, MD, shares tips for recognizing and addressing tinea at the DERM 2025 conference.

DERM 2025 featured tips and tricks for a thorough pruritus diagnosis and treatment strategy from Adam Friedman, MD.

Adam Friedman, MD, FAAD, outlines a stepwise approach to treating chronic hand eczema, from vehicle selection to systemic therapies and future innovations.

Adam Friedman, MD, FAAD, breaks down how to differentiate chronic hand eczema from similar conditions using history, morphology, and key clinical clues.

Renata Block, DMSc, MMS, PA-C, speaks with Adam Friedman, MD, FAAD, on innovative teledermatology initiatives in Washington, DC, addressing health care disparities and enhancing community access.

In part 3 of this conversation, Adam Friedman, MD, FAAD, discusses the need for unity in advancing lichen planus care and research.

In part 2 of this conversation, Adam Friedman, MD, FAAD, discusses new data on lichen planus treatment trends, unmet needs, and the promise of innovative therapies.

Friedman discusses survey findings revealing inconsistent screening, outdated assumptions, and lack of FDA-approved therapies for lichen planus.

Along with his session insights on diet and chronic spontaneous urticaria, Friedman shares tips for navigating the largest dermatology conference in the US.

The top videos under the hashtag, #spironolactone” had low scores on the mDISCERN and GQS scales, according to Adam Friedman, MD, FAAD, senior author of the study.

George Washington University recently earned a Skin Smart Campus designation, championing skin cancer prevention through education, free sunscreen, and UV safety measures.

Personalized care is key to managing hyperhidrosis, blending therapies, addressing adverse effects, and empowering patients with tailored solutions.

Adam Friedman, MD, FAAD, takes a closer look at the emerging landscape of oral treatments for hyperhidrosis and what lies ahead in advancing patient care.

In addition to recapping key highlights from his session, Friedman discusses what is new or upcoming in dermatology that most excites him.

Grant applications are open from now until August 24, 2023, with an anticipated project start/end date of January 2024 through July 2025.